Navigation Links
Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
Date:4/30/2008

SAN BRUNO, CA, April 30 C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community. A new report released this month by the federal Agency for Healthcare Research and Quality revealed a 200 percent increase in potentially fatal diarrheal infections in U.S. hospitals between 2000 and 2005. Additionally, the Association for Professionals in Infection Control and Epidemiology (APIC) is launching the first national prevalence study for C. diff beginning May 1.

According to Patricia Raymond, MD, FACP, FACG, a Chesapeake, Virginia-based gastroenterologist, associate professor of clinical medicine at Eastern Virginia Medical School and host of the soon-to-be-launched Your Health Choice radio program, traditional treatment for C. diff-associated disease is the use of powerful antibiotics such as metronidazole or vancomycin, but one of the most troublesome aspects of the disease is its high rate of recurrence. But studies show that adding the yeast-based probiotic Saccharomyces boulardii (sold under the brand name Florastor®), can cut the rate of recurrence by about half.

Almost one in four CDAD patients will experience a recurrence of symptoms after a round of antibiotic therapy alone, says Dr. Raymond. C. difficile colitis has been in the news recently as more virulent strains are emerging. These more toxic bugs lead to higher rates of surgery for colon removal and death from the infection. Doctors are using everything in their toolboxes to combat C. difficile, and one of our proven tools is Saccharomyces boulardii. When a relapse occurs, use of Florastor during the antibiotic course can help protect against future relapses.

A recent meta-analysis of 31 studies compiled and published in the American Journal of Gastroenterology concluded that S. boulardii is the only probiotic that is effective in fighting recurrent C. diff-associated disease1 Additionally, an article in the March 2006 issue of Gastroenterology and Hepatology showed that use of S. boulardii provided an almost 50 percent decrease in subsequent recurrence among patients who suffered recurrent CDAD symptoms.2 Because Florastor (S. boulardii) is a yeast and not a bacteria, it is not killed by the strong antibiotics that are being used to kill the C. diff bacteria, so it survives in the digestive tract, says Dr. Raymond. When the baby C. diff emerge from their spores, they are greeted by a well-colonized gut, rather than an empty playground.

CDAD is usually indicated by severe abdominal pain, diarrhea with mucous and blood passage, and fever. Dr. Raymond advises those exhibiting these symptoms to see a physician immediately to be tested for the presence of the C. diff toxins and to be prescribed proper antibiotics, since over-the-counter anti-diarrheal agents should be avoided.

Traditional OTC anti-diarrheal products actually slow down the speed of fluids moving through your bowels, and, in the case of C. diff, keeping the bacteria in the bowels is actually a bad thing, she adds.

Healthcare practitioners are advised to adhere to strict hand-washing policies in offices and hospitals to help prevent the spread of this and other types of bacteria.

Florastor has shown in more than 50 years of extensive international use to be safe and effective, with an estimated 1.7 billion daily doses sold to date. It is mentioned by the World Health Organization (WHO) for use in the management of C.diff-associated disease.3


'/>"/>

Contact: Christina Occhipinti
cocchipinti@robinleedyassociates.com
914-241-0086
Biocodex, Inc.
Source:Eurekalert

Related medicine news :

1. Garmin Reports Record First Quarter; Strong Margins and Increased Market Share
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. LMS CALM(R) receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report
4. BASF Podcast: The Chemical Reporter - Why do You Get Garlic Breath?
5. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
6. Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk)
7. Mindray to Report First Quarter 2008 Financial Results on May 7, 2008
8. Kensey Nash Reports Third Quarter Record Revenue and Sales
9. Webcast Alert: HCA announces HCA 1Q 2008 Earnings Report
10. Landauer, Inc. Reports Record Results for Second Quarter
11. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... interactive publication where generations converge and explore the world from different perspectives. By ... Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and ... children with autism spectrum disorder (ASD) to see films in an environment that ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry eye ... ... eye Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... the following questions: What are the key ... positioned in the Global Dry eye market? What are ...
(Date:2/24/2017)... , Feb. 24, 2017 Medical ... ways to increase their self-service capabilities to manage ... Providers (HCPs). New research from consulting ... organizations have developed self-service website portals where HCPs ... is just one of many findings to emerge ...
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: